NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
06. Februar 2024 16:42 ET
|
NexImmune, Inc.
NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
02. Februar 2024 14:00 ET
|
NexImmune, Inc.
NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes
24. Oktober 2023 08:00 ET
|
NexImmune, Inc.
A JDRF funded grant is being used to explore the combination of NexImmune’s antigen specific nanoparticles and an anti-CD3 mAb for prevention and treatment of type 1 diabetes GAITHERSBURG, Md.,...
NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting
19. Oktober 2023 08:00 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., Oct. 19, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by...
NexImmune Announces 1-for-25 Reverse Stock Split
18. Oktober 2023 11:30 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., Oct. 18, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) (the “Company”) a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy
31. August 2023 16:45 ET
|
NexImmune, Inc.
Company retains core capabilities to continue to advance its nanoparticle injection (AIM INJ) platform and potential product candidates in oncology and autoimmune diseases GAITHERSBURG, Md., Aug. ...
NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates
10. August 2023 16:01 ET
|
NexImmune, Inc.
NEXI-001 data presented at ASCO 2023 demonstrates proof-of-concept in patients with relapsed AML after allogeneic hematopoietic cell transplantation (HCT) and refractory to additional chemotherapy or...
NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting
05. Juni 2023 08:01 ET
|
NexImmune, Inc.
- Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory to salvage therapy - NEXI-001 is well tolerated with a favorable safety profile, including no grade > 3...
NexImmune Announces Poster Presentation at the 2023 FOCIS Annual Meeting
22. Mai 2023 16:01 ET
|
NexImmune, Inc.
AIM nanoparticle approach can identify select EBV-specific T cell defects in patients with multiple sclerosis and may enable killing of EBV+ cells believed to be a contributing factor in this disease ...
NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates
15. Mai 2023 16:01 ET
|
NexImmune, Inc.
Company has initiated pre-IND discussions with the FDA for its first AIM INJ indicationNEXI-001 Phase I data to be presented at ASCO 2023 in June GAITHERSBURG, Md., May 15, 2023 (GLOBE NEWSWIRE) --...